scholarly journals Transcription factor egr-1 is involved in phorbol 12-myristate 13-acetate-induced megakaryocytic differentiation of K562 cells.

1994 ◽  
Vol 269 (49) ◽  
pp. 30848-30853
Author(s):  
T Cheng ◽  
Y Wang ◽  
W Dai
Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3431-3431
Author(s):  
Liat Rainis ◽  
Esther Rosenthal ◽  
Sabine Strehl ◽  
Oskar A. Haas ◽  
Shai Izraeli

Abstract About 10% of patients with Down syndrome (DS) are born with a transient megakaryoblastic leukemia. We (Rainis et al. Blood2003; 102:981) and others have demonstrated acquired intrauterine inactivating mutations in the X-linked gene GATA1 in these leukemias. The gene(s) on chromosome 21 that promote the proliferation of these abnormal megakaryoblasts are presently unknown. We hypothesize such a role to the ets transcription factor ERG that is located at the critical DS region on chromosome 21. This hypothesis is based on the close homology between ERG and FLI-1, a transcription factor that induces megakaryopoiesis through cooperation with GATA1. ERG occasionally replaces FLI-1 in the translocation with EWS in Ewing sarcoma and is also involved in the leukemogenic translocation FUS-ERG. However no role for ERG in hematopoiesis has been demonstrated so far. Here we show that (a) ERG is expressed in platelets and in megakaryoblastic cell lines, including those derived from Down Syndrome. (b) ERG is expressed in primary leukemic cells from DS patients. (c) Its expression is induced upon megakaryocytic differentiation (d) ERG collaborates with GATA1 in activation of megakaryocytic promoters in reporter assays; and (e) Forced ectopic expression of ERG in K562 cells induces megakaryocytic differentiation. Thus we provide the first evidence that the ERG gene participate in megakaryopoiesis. Promotion of megakaryopoiesis caused by its overexpression in DS coupled with the differentiation arrest induced by the acquired mutation in GATA1 may explain the high incidence of a congenital megakaryoblastic proliferation disorder in Down Syndrome.


Blood ◽  
2021 ◽  
Author(s):  
Oriol Alejo-Valle ◽  
Karoline Weigert ◽  
Raj Bhayadia ◽  
Michelle Ng ◽  
Hasan Issa ◽  
...  

Given the plasticity of hematopoietic stem/progenitor cells, multiple routes of differentiation must be blocked during acute myeloid leukemia pathogenesis - the molecular basis of which is incompletely understood. Here we report that post-transcriptional repression of the transcription factor ARID3A by miR-125b is a key event in megakaryoblastic leukemia (AMKL) pathogenesis. AMKL is frequently associated with trisomy 21 and GATA1 mutations (GATA1s), and children with Down syndrome are at a high risk of developing this disease. We show that chromosome 21-encoded miR-125b synergizes with Gata1s to drive leukemogenesis in this context. Leveraging forward and reverse genetics, we uncover Arid3a as the main miR-125b target behind this synergy. We demonstrate that, during normal hematopoiesis, this transcription factor promotes megakaryocytic differentiation in concert with GATA1 and mediates TGFβ-induced apoptosis and cell cycle arrest in complex with SMAD2/3. While Gata1s mutations perturb erythroid differentiation and induce hyperproliferation of megakaryocytic progenitors, intact ARID3A expression assures their megakaryocytic differentiation and growth restriction. Upon knockdown, these tumor suppressive functions are revoked, causing a dual megakaryocytic/erythroid differentiation blockade and subsequently AMKL. Inversely, restoring ARID3A expression relieves the megakaryocytic differentiation arrest in AMKL patient-derived xenografts. This work illustrates how mutations in lineage-determining transcription factors and perturbation of post-transcriptional gene regulation can interplay to block multiple routes of hematopoietic differentiation and cause leukemia. In AMKL, surmounting this differentiation blockade through restoration of the tumor suppressor ARID3A represents a promising strategy for treating this lethal pediatric disease.


2008 ◽  
Vol 1780 (5) ◽  
pp. 757-763 ◽  
Author(s):  
Un-Ho Jin ◽  
Ki-Tae Ha ◽  
Kyung-Woon Kim ◽  
Young-Chae Chang ◽  
Young-Coon Lee ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e91557 ◽  
Author(s):  
Xiang-Zhen Kong ◽  
Rong-Hua Yin ◽  
Hong-Mei Ning ◽  
Wei-Wei Zheng ◽  
Xiao-Ming Dong ◽  
...  

Blood ◽  
2002 ◽  
Vol 99 (1) ◽  
pp. 348-356 ◽  
Author(s):  
Milind C. Mahajan ◽  
Sherman M. Weissman

Correct developmental regulation of β-like globin gene expression is achieved by preferential transcription of a gene at a given developmental stage, silencing of other β-like gene promoters, and competition among these promoters for interaction with the locus control region (LCR). Several evolutionarily conserved DNA elements in the promoters of the β-like genes and LCR have been studied in detail, and the role of their binding factors has been investigated. However, the β-globin promoter includes additional evolutionarily conserved sequences of unknown function. The present study examined the properties of a 21-base pair (bp) promoter-conserved sequence (PCS) located at positions −115 to −136 bp relative to the transcription start site of the β-globin gene. A helicaselike transcription factor (HLTF) belonging to the SWI2/SNF2 family of proteins binds to the PCS and a partly homologous sequence in the enhancer region of the LCR hypersensitive site 2 (HS2). Elevation of the level of HLTF in K562 erythroleukemic cells increases β-promoter activity in transient transfection experiments, and mutations in the PCS that remove HLTF-binding regions abolish this effect, suggesting that HLTF is an activator of β-globin transcription. Overexpression of HLTF in K562 cells does not affect the endogenous levels of γ- and ε-globin message, but it markedly activates β-globin transcription. In conclusion, this study reports a transcription factor belonging to the SWI2/SNF2 family, which preferentially activates chromosomal β-globin gene transcription and which has not previously been implicated in globin gene regulation.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4246-4246
Author(s):  
Gauthami S. Jalagadugula ◽  
Danny Dhanasekharan ◽  
A.Koneti Rao

Abstract Human erthroleukemia cells (HEL) differentiate towards megakaryocytic (MK) phenotype when stimulated with phorbol 12-myristate-13-acetate (PMA). We observed that the expression of Gq, a protein that plays a major role in platelet signal transduction, is increased in PMA-treated HEL cells. Western blotting revealed that Gq is upregulated in PMA-treated cells relative to untreated cells. Gq gene induction by PMA treatment was investigated with respect to transcriptional control. Serial 5′-truncations of the upstream region (upto 2727 bp from the ATG) of Gq gene were fused to a luciferase (Luc) reporter gene vector, PGL-3 Basic, and were transiently transfected into HEL cells in the absence and presence of PMA (10 nM). After 24 h, reporter gene activities were measured using Dual Luciferase Reporter Assay System (Promega). A reporter plasmid −1042 bp-Luc with a genomic region −1042/−1 showed a 12 fold activity in PMA treated cells and 4 fold activity in untreated cells. Its truncated plasmid with the genomic region −1036/−1 showed a decrease in luciferase activity by 50% in treated cells; and the activity became identical to that in untreated cells. Further truncation between −1036 and −1011 caused a complete loss of activity in both the cells. Thus, a PMA responsive element was localized to a region between −1042 and −1037 bp. Transcription factor data base search (TFSEARCH) predicted two consensus sites for early growth response factor EGR-1 at -1042/−1031 and −1026/−1015. Gel shift studies were performed with two oligos, −1042/−1012 and −1036/−1012, and nuclear extracts from PMA- treated and untreated cells. The studies with −1042/−1012 probe and extracts from treated cells showed that there was nuclear protein binding, which was abolished by competition with the consensus EGR-1 sequence. In extracts from untreated cells, the protein binding was observed but was not competed with consensus EGR-1 sequence. This suggests EGR-1 binding to the region −1042/−1012 in PMA-treated cells and role for this transcription factor in inducing Gq promoter activity. Moreover, studies on the region −1036/−1012 showed nuclear protein binding that was identical between extracts of untreated and treated cells, and it was not competed with consensus EGR-1 sequence. These findings suggest that, EGR-1 binding is localized to −1042/−1037, but not to −1036/−1012. Conclusion: A PMA responsive sequence (−1042/−1037) was identified in the Gq promoter. Our studies suggest that EGR-1 binding to this sequence confers the PMA responsive activity. These studies provide further evidence that EGR-1 plays an important role in the upregulation of Gq expression during PMA induced megakaryocytic differentiation.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2436-2436
Author(s):  
Laurie A Steiner ◽  
Yelena Maksimova ◽  
Clara Wong ◽  
Vincent Schulz ◽  
Patrick G. Gallagher

Abstract Erythrocyte membrane protein genes serve as excellent models of complex gene loci structure and function, as most encode multiple tissue-, cell-, developmental-, and stagespecific isoforms. Dynamic chromatin modifications participate in the regulatory control of many gene loci. We hypothesize that specific DNA sequences, transcription factors, and chromatin architecture (epigenetic modifications) regulate the tissue-specific expression of erythrocyte membrane protein genes. Advances in genomics technology have permitted rapid identification of DNA sequences bound by transcription factors and other DNAassociated proteins on a genome-wide scale. One technique available for mapping protein-DNA interactions in vivo couples chromatin immunoprecipitation to microarrays that contain regions of genomic DNA (ChIP-chip). We are using DNA obtained from chromatin immunoprecipitations performed with histone and erythroid transcription factor antibodies hybridized to genomic DNA microarray chips (ChIP-chip) to study the regulation of membrane protein genes in erythroid and nonerythroid cells. Chromatin immunoprecipitations (ChIP) were done in erythroid (K562) and non-erythroid (HeLa) cell lines using antibodies against H3 tri-methyl lysine 4 (H3K4me3, a marker of active chromatin) and the erythroid transcription factors GATA-1 and NF-E2. The chromatin resulting from these ChIPs was hybridized to a custom made NimbleGen high density human genomic DNA microarray (chip) focused on 15 genes critical to the erythrocyte membrane: ankyrin (ANK1), α-spectrin (SPTA1), β-spectrin (SPTB), band 3 (SLC4A1), β-adducin (ADD2), α-adducin (ADD1), γ-adducin (ADD3), ICAM-4, Erythroid Associated Membrane Protein (ERMAP), Protein 4.1 (EPB41), Protein 4.2 (EPB42), Dematin (ERPB49), β-Actin (ACTB), tropomodulin (TMOD1), and tropomyosin (TPM3). Probes for the chip were ~50bp in length with Tm ≥ 76°C, tiled every 65bp. From 50–100kb of flanking DNA was included on the chip for each locus. The Tamalpais peak calling algorithm using L1–L3 level of stringency (Genom Res16:595, 2006) was used to analyze the resulting data and identify regions of epigenetic modifications and transcription factor binding. Fourteen of 15 genes were enriched for H3K4me3 at promoter and transcriptional start sites (TSS) in K562 cells, with one gene, TMOD1, demonstrating a large peak of enrichment 5′ of the currently identified TSS, but not at the promoter. Two compact genes, β-actin and ICAM4, had H3K4me3 enrichment at the promoter and throughout gene. A total of 19 GATA-1 sites and 18 NF-E2 sites were identified. GATA-1 sites were found in 8 of 15 genes or in their flanking DNA. Three sites were in the 5′ flanking DNA, 1 site was at the promoter (~500bp from transcription start site, TSS), 12 sites were in introns, and 3 sites were in the 3′ flanking DNA. NF-E2 sites were found in 10 of 15 genes or their flanking DNA. 6 sites were in the 5′ flanking DNA, 1 site was at the promoter (~200bp from TSS), 8 sites were in introns, and 3 sites were in the 3′ flanking DNA. 18 of 19 GATA-1 sites (95%) and 13 of 18 NF-E2 sites (72%) were validated using qPCR-based quantitative ChIP. In K562 cells, 15 of 19 (79%) validated GATA-1 sites were associated with regions of chromatin enriched for H3K4me3, suggesting that ~a fifth of GATA-1 sites were in regions of inactive chromatin, consistent with a repressor function for GATA-1 at these sites. Eleven of 13 validated NF-E2 sites (85%) were associated with regions of K562 chromatin enriched for H3K4me3. In HeLa cells, the sites of GATA-1 and NF-E2 occupancy identified in K562 cells were almost never associated with H3K4me3 enrichment. GATA-1 and NF-E2 sites identified by Tamalpais and validated in K562 cells were analyzed in CD71-bright, glycophorin A-bright cultured primary erythroid cells using conventional quantitative ChIP analyses. Of the 13 NF-E2 sites identified in K562 cells, all 13 were also occupied in primary erythroid cells. ChIP-chip is a powerful tool for studying chromatin architecture and identifying transcription factor binding sites in complex genetic loci such as the erythrocyte membrane protein genes. It will be useful in constructing a comprehensive catalogue of chromatin architecture and transcription factor binding of genes expressed in erythroid cells.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2393-2393 ◽  
Author(s):  
Rabindranath Bera ◽  
Der-Cherng Liang ◽  
Ming-Chun Chiu ◽  
Ying-Jung Huang ◽  
Sung-Tzu Liang ◽  
...  

Abstract Abstract 2393 Somatic mutations of ASXL1 gene have been described in patients with myeloid malignancies and were associated with inferior outcomes. ASXL1 mutations have also been detected in myeloid blast crisis of chronic myeloid leukemia (CML) patients. The mechanisms of acute myeloid leukemia (AML) transformation and functional role of ASXL1 mutations in the leukemogenesis remain to be determined. Recently, we identified PHD domain deletion mutations (R693X and L885X) in patients with CML in myeloid blast crisis and/or AML with minimal differentiation (M0). In the present study, we aimed to investigate the role of PHD domain deletion mutations in the pathogenesis of AML transformation. The K562 cells carrying Philadelphia chromosome, serves as a model to study the molecular mechanisms associated with leukemogenesis. Our result showed that R693X/L885X mutations inhibited PMA-treated megakaryocytic differentiation with the change of physiological characteristic features and suppressed the induction of CD61, a specific cell surface marker of megakaryocytes. We also found that FOSB, a member of Fos family of AP-1 transcription factors was down-regulated in K562 cells expressing R693X and L885X compared to wild-type ASXL1 during PMA-mediated megakaryocytic differentiation. Examination of intracellular signaling pathways showed that the mutant ASXL1 protein prevented PMA-induced megakaryocytic differentiation through the inactivation of ERK, AKT and STAT5 which are required for differentiation. Further, ASXL1 depletion by shRNA in K562 cells led to enhanced cell proliferation, increased colony formation and impaired PMA-mediated differentiation. Previous studies in Drosophila had revealed that Asxl forms the protein complexes of both Trithorax and Polycomb groups that are required for maintaining chromatin in both activated and repressed transcriptional states. By using Western blot analysis, we demonstrated that PHD domain deletion mutations of ASXL1 significantly suppressed the transcriptionally repressive mark H3K27 trimethylation, however no effect on methylated H3K4 (H3K4me2 and H3K4me3), an active histone mark in K562 cells. Co-immunoprecipitation analysis revealed that wild-type, but not PHD domain deletion mutations of ASXL1 interact with EZH2, a member of the polycomb repressive complex 2 (PRC2). Importantly, PHD deletion mutations or downregulation of ASXL1 resulted in the suppression of EZH2 in K562 cells. Our study demonstrated that PHD deletion mutations of ASXL1 resulted in a loss-of-function which exhibited direct effects on the proliferation and differentiation and also proposed a specific role for ASXL1 in epigenetic regulation of gene expression in K562 cells. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3507-3507
Author(s):  
Yuanyuan Kang ◽  
Bhavita Patel ◽  
Kairong Cui ◽  
Keji Zhao ◽  
Yi Qiu ◽  
...  

Abstract Abstract 3507 T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant disease of thymocytes that mainly affects children and has very poor prognosis with high rates of relapse. A prominent feature observed in 60% of T-ALL childhood patients is the ectopic expression of a key hematopoietic transcription factor TAL1/SCL. Although several enhancers has been identified to play an important role in normal hematopoietic differentiation, the histone modification patterns and chromatin organization over the whole TAL1 locus reveled that none of them is active in T-ALL cell lines such as Jurkat and Rex cells. It remains currently unknown how TAL1 is activated in the majority of T-ALL patients lacking the TAL1 locus rearrangements. To understand the molecular mechanism underlying regulation of the TAL1 oncogene in leukemic T-cells, we employed circularized chromosome conformation capture (4C) methodology to identify new regulatory elements that activate TAL1 specifically in T-ALL leukemia. Using the TAL1 promoter 1a as the bait, we discovered that the TAL1 promoter 1a interacts with the TIL16 element (TAL1 interacting locus in chromosome 16) that is located at ∼15 Kb downstream of T-cell specific CD2BP2 gene in T-ALL cell line Jurkat, but not in erythroid progenitor K562 cells. The CD2BP2 protein is a cellular adapter protein that was originally identified as a binding partner of the T cell adhesion protein CD2 in the context of T cell signaling. The TIL16 element contains the bind sites for several transcription factors that are important for hematopoiesis such as C-Maf, Pax5, HoxA7 and USF2. The inter-chromosomal interaction between the TIL16 and the TAL1 promoter 1a was further confirmed by chromosome conformation capture (3C) assay in three TAL1 over-expressing T-ALL cell lines, Jurkat, REX and Molt4, but not in K562 cells. Recent genome wide study has correlates H3K4 mono- or dimethyl marks with distal enhancers while trimethyl H3K4 is enriched in promoters of active genes. To further test if the TIL16 acts as T-cell specific enhancer for TAL1 activation in T-ALL cells, we carried out ChIP-seq and ChIP analysis in CD4 T cells, Jurkat, and K562 cells. We found that the TIL16 element is specifically marked by H3K4me1 in Jurkat and CD4+ T-cells but not in K562 cells. The enrichment of H3K4me1 is correlated with the binding of c-Maf, a T-cell specific transcription factor. To further test whether the TIL16 element contributes to transcription activity, a DNA fragments containing the TIL16 element were cloneed into SV40 minimal promoter driven luciferase reporter and introduced into K562 and several T-ALL cell lines. Compared to the pGL3-SV40 vector that showed only minimal luciferase activity, the 1 Kb TIL element specifically activated transcription of the luciferase reporter in T-ALL cells, but not in erythroid progenitor K562 cells suggesting that the TIL16 element functions as a T-cell specific TAL1 enhancer. Thus, our data revealed a novel epigenetic mechanism by which the TAL1 oncogene is ectopically activated in T-cell leukemia. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document